Cargando…
Pembrolizumab-related renal toxicities: diagnosis first, treatment later
Checkpoint inhibitors are increasingly used to treat different types of malignancy and have been associated with renal toxicities. In this issue, Izzedine et al. report on the incidence of pembrolizumab-associated renal toxicity in a French single-centre nephrology referral centre. They report an es...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366137/ https://www.ncbi.nlm.nih.gov/pubmed/30746131 http://dx.doi.org/10.1093/ckj/sfy114 |
_version_ | 1783393560827002880 |
---|---|
author | Sprangers, Ben |
author_facet | Sprangers, Ben |
author_sort | Sprangers, Ben |
collection | PubMed |
description | Checkpoint inhibitors are increasingly used to treat different types of malignancy and have been associated with renal toxicities. In this issue, Izzedine et al. report on the incidence of pembrolizumab-associated renal toxicity in a French single-centre nephrology referral centre. They report an estimated incidence of pembrolizumab-related renal toxicities of 1.77% and most notably the most common histologic lesion was acute tubular injury (not acute tubulo-interstitial nephritis). This study further highlights the importance of performing a thorough nephrological workup including kidney biopsy in patients experiencing renal toxicities while receiving pembrolizumab treatment. |
format | Online Article Text |
id | pubmed-6366137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63661372019-02-11 Pembrolizumab-related renal toxicities: diagnosis first, treatment later Sprangers, Ben Clin Kidney J Drug-Induced Nephropathies Checkpoint inhibitors are increasingly used to treat different types of malignancy and have been associated with renal toxicities. In this issue, Izzedine et al. report on the incidence of pembrolizumab-associated renal toxicity in a French single-centre nephrology referral centre. They report an estimated incidence of pembrolizumab-related renal toxicities of 1.77% and most notably the most common histologic lesion was acute tubular injury (not acute tubulo-interstitial nephritis). This study further highlights the importance of performing a thorough nephrological workup including kidney biopsy in patients experiencing renal toxicities while receiving pembrolizumab treatment. Oxford University Press 2018-12-01 /pmc/articles/PMC6366137/ /pubmed/30746131 http://dx.doi.org/10.1093/ckj/sfy114 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Drug-Induced Nephropathies Sprangers, Ben Pembrolizumab-related renal toxicities: diagnosis first, treatment later |
title | Pembrolizumab-related renal toxicities: diagnosis first, treatment later |
title_full | Pembrolizumab-related renal toxicities: diagnosis first, treatment later |
title_fullStr | Pembrolizumab-related renal toxicities: diagnosis first, treatment later |
title_full_unstemmed | Pembrolizumab-related renal toxicities: diagnosis first, treatment later |
title_short | Pembrolizumab-related renal toxicities: diagnosis first, treatment later |
title_sort | pembrolizumab-related renal toxicities: diagnosis first, treatment later |
topic | Drug-Induced Nephropathies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366137/ https://www.ncbi.nlm.nih.gov/pubmed/30746131 http://dx.doi.org/10.1093/ckj/sfy114 |
work_keys_str_mv | AT sprangersben pembrolizumabrelatedrenaltoxicitiesdiagnosisfirsttreatmentlater |